Shannon Stephen, Vaca Connan, Jia Dongxuan, Entersz Ildiko, Schaer Andrew, Carcione Jonathan, Weaver Michael, Avidar Yoav, Pettit Ryan, Nair Mohan, Khan Atif, Foty Ramsey A
Department of Surgery, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States of America.
Department of Radiation Oncology, Cancer Institute of New Jersey, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States of America.
PLoS One. 2015 Aug 18;10(8):e0135951. doi: 10.1371/journal.pone.0135951. eCollection 2015.
Despite resection and adjuvant therapy, the 5-year survival for patients with Glioblastoma multiforme (GBM) is less than 10%. This poor outcome is largely attributed to rapid tumor growth and early dispersal of cells, factors that contribute to a high recurrence rate and poor prognosis. An understanding of the cellular and molecular machinery that drive growth and dispersal is essential if we are to impact long-term survival. Our previous studies utilizing a series of immortalized GBM cell lines established a functional causation between activation of fibronectin matrix assembly (FNMA), increased tumor cohesion, and decreased dispersal. Activation of FNMA was accomplished by treatment with Dexamethasone (Dex), a drug routinely used to treat brain tumor related edema. Here, we utilize a broad range of qualitative and quantitative assays and the use of a human GBM tissue microarray and freshly-isolated primary human GBM cells grown both as conventional 2D cultures and as 3D spheroids to explore the role of Dex and FNMA in modulating various parameters that can significantly influence tumor cell dispersal. We show that the expression and processing of fibronectin in a human GBM tissue-microarray is variable, with 90% of tumors displaying some abnormality or lack in capacity to secrete fibronectin or assemble it into a matrix. We also show that low-passage primary GBM cells vary in their capacity for FNMA and that Dex treatment reactivates this process. Activation of FNMA effectively "glues" cells together and prevents cells from detaching from the primary mass. Dex treatment also significantly increases the strength of cell-ECM adhesion and decreases motility. The combination of increased cohesion and decreased motility discourages in vitro and ex vivo dispersal. By increasing cell-cell cohesion, Dex also decreases growth rate of 3D spheroids. These effects could all be reversed by an inhibitor of FNMA and by the glucocorticoid receptor antagonist, RU-486. Our results describe a new role for Dex as a suppressor of GBM dispersal and growth.
尽管进行了手术切除和辅助治疗,但多形性胶质母细胞瘤(GBM)患者的5年生存率仍低于10%。这种不良预后很大程度上归因于肿瘤的快速生长和细胞的早期扩散,这些因素导致了高复发率和不良预后。如果我们想要影响长期生存率,了解驱动肿瘤生长和扩散的细胞及分子机制至关重要。我们之前利用一系列永生化GBM细胞系的研究,确立了纤连蛋白基质组装(FNMA)激活、肿瘤凝聚力增加和扩散减少之间的功能因果关系。FNMA的激活是通过用地塞米松(Dex)处理实现的,地塞米松是一种常用于治疗脑肿瘤相关水肿的药物。在这里,我们利用广泛的定性和定量分析方法,以及使用人GBM组织微阵列和新鲜分离的原代人GBM细胞,这些细胞既可以作为传统的二维培养物生长,也可以作为三维球体生长,以探究Dex和FNMA在调节各种可显著影响肿瘤细胞扩散的参数中的作用。我们发现,人GBM组织微阵列中纤连蛋白的表达和加工存在差异,90%的肿瘤显示出一些异常或缺乏分泌纤连蛋白或将其组装成基质的能力。我们还表明,低传代原代GBM细胞的FNMA能力各不相同,而Dex处理可重新激活这一过程。FNMA的激活有效地将细胞“粘”在一起,防止细胞从原发肿块中脱离。Dex处理还显著增加了细胞与细胞外基质的粘附强度并降低了细胞运动性。凝聚力增加和运动性降低的共同作用抑制了体外和体内的扩散。通过增加细胞间凝聚力,Dex还降低了三维球体的生长速率。这些作用均可被FNMA抑制剂和糖皮质激素受体拮抗剂RU-486逆转。我们的结果描述了Dex作为GBM扩散和生长抑制剂的新作用。